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Abstract
Background: Bisphenol A (BPA), a high production chemical commonly found in plastics, has drawn great attention
from researchers due to the substance’s potential toxicity. Using data from three National Health and Nutrition
Examination Survey (NHANES) cycles, we explored the consistency and robustness of BPA’s reported effects on
coronary heart disease and diabetes.
Methods And Findings: We report the use of three different statistical models in the analysis of BPA: (1) logistic
regression, (2) log-linear regression, and (3) dose-response logistic regression. In each variation, confounders were
added in six blocks to account for demographics, urinary creatinine, source of BPA exposure, healthy behaviours,
and phthalate exposure. Results were sensitive to the variations in functional form of our statistical models, but no
single model yielded consistent results across NHANES cycles. Reported ORs were also found to be sensitive to
inclusion/exclusion criteria. Further, observed effects, which were most pronounced in NHANES 2003-04, could not
be explained away by confounding.
Conclusions: Limitations in the NHANES data and a poor understanding of the mode of action of BPA have made it
difficult to develop informative statistical models. Given the sensitivity of effect estimates to functional form,
researchers should report results using multiple specifications with different assumptions about BPA measurement,
thus allowing for the identification of potential discrepancies in the data.
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Introduction
Bisphenol A (BPA) is an organic compound, commonly used
in the synthesis of plastics and epoxy resins [1]. It is estimated
that roughly ~2.2 million tons of BPA were produced in 2010,
making it one of the world’s mostly widely manufactured
chemicals [2]. Due to its hormone-like properties, BPA has
attracted significant attention as a potentially toxic substance.
To date over 5000 papers have been published to assess
exposure to and toxicity of BPA [3]. Yet there remains little
consensus whether BPA represents a true threat to consumer
health [1,4], greatly complicating matters for the general public
and policy-makers.
Most experts agree that there is widespread exposure to
BPA. The Centers for Disease Control and Prevention (CDC)
reported detectable levels of BPA in 93% of Americans in
2003-04 [5]. Similarly high levels of BPA exposure have also
been reported in Canadian, European, and Asian populations
[6,7]. It is believed that BPA most commonly enters the body
via the digestive tract. Studies have shown that BPA can leach
out of food packaging and bottling materials, leading to
widespread ingestion of the chemical [8,9]. Less common
dermal, via cash register receipts, and airborne, via dust
inhalation, exposures have also been observed [1,10].
Unlike exposure assessments, the toxicity of BPA remains
hotly debated. As a weak endocrine disruptor, BPA has the
potential to alter hormonally regulated processes in the human
body [11]. Latent and sustained exposure to BPA has been
linked to a battery of chronic conditions including: cancer,
namely of the prostate [12,13], cardiac arrhythmias [14],
disrupted pancreatic β-cell function, which increases risk for
type II diabetes [15],, reduced fertility [16], asthma [17],
metabolic syndrome [18], and obesity [19]. BPA, also believed
to demonstrate teratogenic effects, may alter neurocognitive
development in exposed embryos and fetuses [13,20].
However, these toxicology studies have failed to gain wide
spread acceptance for numerous reasons including: difficulty
extrapolating data from animal models to humans, lack of
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consistency in study end points, conflicting reports, and
uncertainties in exposure assessment [3].
Epidemiological examinations of BPA toxicity have yielded
similarly mixed results. A 2008 study, by Lang et al., reported
statistically significant relationships between BPA exposure
and cardiovascular disease (CVD) and diabetes in the National
Health and Nutrition Examination Survey (NHANES) [21].
However, subsequent efforts to produce comparable results
have yielded mixed results, with some supporting [22,23] and
others challenging [24-26]. We hypothesized that conflicting
epidemiological results could be attributed to one of two
reasons: (1) positive associations could be explained away by
confounding, or (2) results were sensitive to the functional form
of the applied statistical model. In order to test our hypotheses,
we replicated the results from Lang et al.’s paper and extended
their work by including multiple NHANES cycles to increase
sample size, expanding the number of covariates included in
the regression models, and varying the functional form of the
statistical model.
Materials and Methods
NHANES is a biennial, cross-sectional survey that measures
the health status and dietary patterns of the non-
institutionalized, civilian US population [27]. The survey uses a
stratified, multistage probability design to identify a
representative subset of the US population. NHANES subjects
undergo several days of questionnaires and tests, yielding a
wide range of information on demographics, socioeconomics,
nutrition, medical status, dental status, and physiological/
laboratory measurements. This study includes data from three
NHANES cycles: 2003-04, 2005-06, and 2007-08, which will
now be referred to as 03-04, 05-06, and 07-08 respectively.
Ethics Statement
With approval from the National Center for Health Statistics
IRB, the Centers for Disease Control and Prevention (CDC)
releases NHANES data to the public. All participants in the
survey are required to provide informed consent.
Exposure and Outcome Assessment
During each NHANES cycle, one third of the subjects were
randomly selected to provide urine samples. Urinary BPA, free
and conjugated, was then measured by high-performance
liquid chromatography-isotope dilution tandem mass
spectroscopy (MS/MS) with peak focusing [28]. All
measurements were completed by the Division of
Environmental Health Laboratory Sciences at the National
Center for Environmental Health. All measurements below the
lower limit of detection (LLOD) - measured at 0.36 ng/ml in
03-04 and 0.40 ng/ml in 05-06 and 07-08 - are known to be
unreliable. Consistent with prior studies, we assigned a value
of LLOD/√2, or 0.28 ng/ml, to all values below the limit in each
NHANES cycle [23,24].
Health outcomes, both coronary heart disease (CHD) and
diabetes, were self-report measures collected via
questionnaire. Subjects were asked if a doctor or other health
professional had ever told them that he/she has CHD or
diabetes. For the purposes of our analysis, subjects reporting
borderline diabetes (defined as having blood sugars higher
than normal, but not high enough to be classified as diabetes)
were considered disease positive. To address the problem of
multiple comparisons, when drawing conclusions over two
outcomes (CHD and diabetes), we took the conservative
Bonferoni approach and treated p<0.025 as being indicative of
statistical significance.
Study Population
Subjects ranged in age from 18-74. Children were excluded
as the diseases of interest are rarely observed in their age
group. The elderly, >74 years, were excluded to minimize the
occurrence of co-morbidities in the study population. One
subject was excluded from the 03-04 for missing a urinary
creatinine value, while another subject was omitted from 05-06
for having an implausible mono-isobutyl phthalate
concentration (nearly ~2 orders of magnitude larger than the
next biggest value). Prior studies also excluded subjects for
having urinary concentrations in excess of >80.1 ng/ml [23,24].
However, the aforementioned exclusion rule was based on the
range of BPA values observed in the 03-04 dataset, rather than
biologic plausibility [23]. Statistical models initially included
subjects in the full range of reported BPA concentrations in
each NHANES cycle. In order to assess sensitivity to BPA-
based exclusion criteria, we repeated our analysis two times:
once omitting subjects with BPA concentration >80.1 ng/ml,
and again by omitting subjects below the LLOD and above the
99th percentile. The first exclusion called for the removal of 9
subjects, while the second dropped another 404 subjects.
Statistical Analysis
NHANES uses a complex, multistage, probability sampling
design to ensure generalizability of the results to the larger US
population. In accord with NHANES Analytic and Reporting
Guidelines, weighted estimates were calculated, including
multi-year sampling weights [29]. Confidence intervals were
calculated, with the provided ‘masked variance pseudo-psu’
and ‘pseudo-stratum’ variables, using a Taylor Series
Linearization method. Analysis was carried out in Stata /IC v.
12.1.
Throughout the analysis, the parameter of interest is the
relationship between BPA and either CHD or diabetes. Ideally,
one would like to know the causal relationship between BPA
and each outcome, but this is unlikely to be achieved using
observational data without any (quasi-) random assignment. As
one way of gauging whether we have in fact estimated a causal
parameter is to assess how robust estimates are to alternative
model specifications.
We initially replicated the results from Lang et al.’s study on
the 2003-04 NHANES data [21]. Using logistic regressions, the
authors created two models to estimate odd ratios (ORs) of
self-reported disease per 1-standard deviation increase in BPA
concentration. The first model adjusted for age, sex, and
urinary creatinine concentration (Model 1). The second model
expanded the regression model to include race/ethnicity,
income, smoking, body mass index, and waist circumference
(Model 2). We created four more models to probe the
Modelling BPA & Health Outcomes
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importance of potential confounders. Each model involved
sequentially adding a new block of covariates. First, we
adjusted for additional demographic information including:
veteran/military status, citizenship status, marital status,
household size, pregnancy status, language at subject
interview, health insurance coverage, and employment status
in the prior week (Model 3). We further controlled for potential
sources of BPA exposure including: consumption of bottled
water in the past 24 hrs [30], consumption of alcohol [9], and
annual consumption of tuna fish [31] (Model 4). We then
adjusted for ‘healthy behaviours’ as exhibited by: the presence
of emotional support in one’s life, being on a diet, using a water
treatment device, access to a routine source of health care,
being vaccinated for Hepatitis A or B, consumption of dietary
supplements (vitamins or minerals), and inability to purchase
balanced meals on a consistent basis (Model 5). Finally, we
controlled for exposure to phthalates, another potentially toxic
substance commonly found in plastics with BPA [32]. Our
regression model includes three metabolites commonly found
in the human body after phthalate consumption: (2-ethylhexyl)
phthalate (MEHP), mono-isobutyl phthalate (MiBP), and mono-
n-butyl phthalate (MeBP) (Model 6). All pooled analyses
controlled for survey cycle as well. Phthalate data was not
available in 03-04; thus odds ratios (ORs), for Model 6, are not
reported for the 03-04 survey, nor the pooled data. Tables S1-
S4 provide further information on covariates, such as their
unadjusted correlations to BPA and NHANES variable
identifier, included in Models 3-6. Each model was compared to
the prior model, in the pooled data, using the Hausman statistic
[33], Akaike information criterion (AIC) and Bayesian
information criterion (BIC).
Urinary creatinine was included in all regression models to
adjust for variable diluteness in spot urine samples [34].
Creatinine was measured using a Jaffe reaction in 03-04 and
05-06 and using an enzymatic method in 07-08. Creatinine
measurements were made with Beckman CX3 Analyzer and
Roche/Hitachi ModP Analyzer in 03-04/05-06 and 07-08
respectively. We used NHANES recommended stepwise
transformation on the 03-04/05-06 data to account for
interference effects of the Jaffe reaction, making the creatinine
data between NHANES cycles more comparable [35].
Finally, we varied the functional form of our statistical model
by mimicking two alternatives found in literature: a log-linear
exposure-response relationship [24] and a dose-response
logistic regression [22]. In the first variation, we carried out
logistic regression analysis with a log-transformed urinary BPA
values, thus creating a log-linear relationship between
exposure and response. The log-linear model can better
account for diminishing linearity, as outcomes plateau, in high-
dose exposure regions [36]. For consistency across body
metabolites, phthalate and creatinine measurements were log-
transformed in this model as well. In the dose-response
regression, exposure was transformed into a categorical
variable by quartile of BPA exposure (<1.1 ng/ml, 1.2-2.2
ng/ml, 2.3-4.2 ng/ml, and >4.2 ng/ml), with the lowest quartile
serving as the reference group. If the assumptions of linearity
hold, then we would expect to see steadily increasing ORs
across increasing quartiles of exposure. The dose-response
analysis may help uncover whether adverse effects, if
observed, plateau in high-dose regions. Analysis of marginal
effects was carried out, in each functional form variation, to
assess how diabetes and CHD risk changed with small
changes in BPA exposure. Finally, analyses were repeated
with an interaction term between BPA and survey cycle, in
order to assess the consistency of estimates across cycles.
Results
The entire sample included 4658 subjects with 1455 in
03-04, 1498 in 05-06, and 1705 in 07-08. Unadjusted mean
BPA concentrations dropped across survey cycles from 4.78 to
4.16 to 3.76 ng/ml in 03-04, 05-06, and 07-08 respectively.
Median BPA exposure followed a similar, but less dramatic,
downward trend across NHANES cycles, as it decreased from
2.8 to 2.1 to 2 ng/ml. Figure 1 provides a box plot with median,
25th percentile, and 75th percentile creatinine-corrected BPA
concentrations across NHANES survey cycles. Furthermore,
only 4,211 subjects reported their CHD status, with 144
responding in the affirmative. Similarly, 487 out of 4,654
subjects reported having diabetes or borderline diabetes.
Table 1 provides a breakdown, with weighted percentages,
of demographic characteristics of the subjects in each
NHANES cycles. In each survey cycle, subjects were
separated by low and high exposure, based off their urinary
BPA concentration relative to the median value. Roughly 52%
of individuals with high exposure were male, while only ~46%
of those with low exposure were male, suggesting an increased
risk for BPA exposure among males. Table 1 further suggests
that younger subjects, non-Hispanic blacks, individuals with a
HS degree or equivalent, families in lower income brackets,
individuals with a high BMI, and current smokers are at risk for
increased BPA exposure. Tables S1-S4 provide further
information on the characteristics, sources of BPA exposure,
Figure 1.  A box-and-whisker plot of creatinine-corrected
and weighted Bisphenol A exposure in NHANES 03-04 (N =
1,455), 05-06 (N = 1,498), 07-08 (N = 1,705).  Outliers are not
depicted.
doi: 10.1371/journal.pone.0079944.g001
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and patterns of healthy behaviour in the participants across
NHANES cycles.
Odds ratios (ORs) from the sequential logistic regression
models, both linear and log-linear, can be found in Tables 2-4,
as well as Tables S5-S12. Table 2 provides ORs for
associating CHD with a 1-standard deviation (1-SD) increase in
BPA, separately by NHANES cycle and all cycles pooled
together. The ORs for 03-04 were statistically significant. The
ORs for 05-06 were also statistically significant, but
considerably smaller in magnitude. The ORs for 07-08 were
even smaller and were no longer significant. The estimates
from the pooled sample lie in between and were statistically
significant. By contrast, Table 3 shows that ORs for diabetes
indicate significantly increased risk in the 03-04 sample only.
ORs in 05-06 are not statistically significant, while ORs in
07-08 demonstrated a non-significant protective effect. ORs
remained fairly stable, for both CHD and diabetes, with the
addition of covariates from Model 1 to Model 6. Further, the
Hausman test never reached statistical significance, confirming
that confounding variables had very little impact on effect
estimates. However, the overall fit of the model always
improved as covariates were added as indicated by decreasing
trends in both AIC and BIC over the various model
specifications (Tables S13-S14).
Most ORs from the log-linear model for CHD achieved
significance at the 95% confidence level in 03-04, 07-08, and
pooled sample (Table 4). However significance was lost in
most instances after application of the Bonferoni correction.
Applying the log-linear transformation to self-reported diabetes
yielded similar results (in comparison to logistic regression
Table 1. Weighted percentages of sociodemographic characteristics separated by NHANES cycle and level of exposure,
where Low ≤2.2 ng/ml and High >2.2 ng/ml.
  NHANES 03-04 NHANES 05-06 NHANES 07-08 Pooled p-valuea
  N = 1455 N = 1498 N = 1705 N = 4658  
  Low (%) High (%) Low (%) High (%) Low (%) High (%) Low (%) High (%)  
Sex Male 43.63 51.76 45.34 53.9 48.76 49.99 46.08 51.81 <0.001
 Female 56.37 48.24 54.66 46.1 51.24 50.01 53.92 48.19  
Age Group 18-29 17.45 28.13 16.94 31.1 18.54 30.26 17.64 29.7 <0.001
 30-39 17.63 22.45 19.92 19.54 18.88 19.77 18.93 20.72  
 40-49 24.33 21.69 22.68 21.74 22.86 20 23.19 21.15  
 50-59 19.08 16.6 21.73 14.28 20.55 17.61 20.59 16.25  
 60-74 21.52 11.13 18.73 13.35 19.18 12.36 19.65 12.18  
Race/Ethnicity Mexican American 8.58 8.36 7.82 8.96 9.36 8.85 8.57 8.7 <0.001
 Other Hispanic 4.49 4.13 2.98 4.02 4.81 4.95 4.03 4.37  
 Non-Hispanic white 70.53 68.24 74.07 65.65 69.64 67.51 71.55 67.24  
 Non-Hispanic black 6.95 15.18 9.52 15.97 8.69 15.38 8.52 15.48  
 Other 9.46 4.09 5.61 5.4 7.5 3.31 7.33 4.22  
Education Less than <HS 17.5 18.5 13.91 19.06 19.5 19.3 16.86 18.92 0.010
 HS or equivalent 23.24 27.87 23.6 26.35 24.87 27.43 23.95 27.28  
 Greater than HS 59.25 53.64 62.49 54.34 55.62 53.27 59.19 53.72  
 Unknown 0 0 0 0.26 0 0 0 0.07  
Household <$20,000 13.61 17.72 10.45 16.54 12.71 13.29 12.11 15.93 <0.001
Income $20,000-$35,000 17.07 18.97 14.59 18.77 15.22 17.62 15.49 18.47  
 $35,000-$65,000 25.96 27.74 25.94 26.28 21.2 24.76 24.28 26.34  
 >$65,000 37.22 30.41 44.32 34.36 45.36 37.93 42.75 34.03  
 Unknown 6.14 5.17 4.71 4.05 5.51 6.4 5.38 5.24  
BMI <18.5 2.03 2.22 3.17 2.01 0.99 1.49 2.09 1.92 0.005
 18.5-24.9 36.21 31.66 32.49 28.34 35.8 30.22 34.67 30.22  
 25.0-29.9 33.09 28.32 32.03 30.87 30.33 29.58 31.72 29.48  
 30-34.9 17.94 21.55 16.9 21.16 19.21 17.81 18 20.21  
 >=35 9.13 14.6 14.65 17.18 12.36 20.47 12.34 17.27  
 Unknown 1.59 1.66 0.76 0.45 1.31 0.42 1.18 0.9  
Smoking Status Never smoked 51.58 46.56 50.01 46.98 48.87 50.89 50.04 48.1 0.005
 Former smoker 24.91 20.79 23.25 19.95 24.09 22 24 20.94  
 Some days 3.73 4.93 3.33 2.92 4.26 4.11 3.77 4.07  
 Every day 17.86 22.56 21.33 24.37 19.11 17.83 19.6 21.54  
 Unknown 1.91 5.17 2.08 5.78 3.67 5.18 2.59 5.35  
a. Pearson’s chi-square tests were carried out, using survey weights, on the data from the pooled sample.
doi: 10.1371/journal.pone.0079944.t001
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analysis, Table 2), with the exception that statistical
significance was achieved in the pooled sample (Table 5).
Similar to the linear model, ORs were robust to confounding as
indicated by non-significant Hausman tests. In terms of
marginal effects, a one standard deviation increase in BPA was
associated with a 0.3 to 0.5 increase in the probability of CHD
and diabetes across the various models, while ten-fold
increases in BPA were associated with 0.6 to 1.3 percent
changes (Tables S17-S20). Marginal effects, for the logistic
model, were significant for CHD, but not for diabetes. The
opposite pattern of significance was observed in the log-linear
model. Given that the rate of CHD and diabetes were relatively
small in the study population (3.5 and 11.7% respectively),
these changes in risk were rather substantial.
In the analysis of CHD risk, application of initial exclusion
criteria, or removing subjects with BPA >80.1 ng/ml, led to a
near ~30% increase in estimated ORs in the pooled data
(Table S2 and S5). Furthermore, excluding subjects below the
Table 2. Logistic regression analysis of self-reported CHD per standard deviation increase of Bisphenol A exposure for
NHANES 03-04 (N = 1,455), 05-06 (N = 1,498), 07-08 (N = 1,705), and a pooled sample (N = 4,658).
 NHANES 03-04 NHANES 05-06 NHANES 07-08 Pooled   
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Hausman Statistic (p) †
Model 1 1.408* (1.093 - 1.815) 1.130 (0.959 - 1.331) 1.058 (0.888 - 1.259) 1.140* (1.025 - 1.268) --
Model 2 1.596* (1.126 - 2.262) 1.179 (1.014 - 1.371) 1.116 (0.921 - 1.353) 1.163* (1.038 - 1.303) 0.998 (0.607)
Model 3 1.713** (1.180 - 2.486) 1.243 (1.020 - 1.516) 1.101 (0.883 - 1.372) 1.158* (1.026 - 1.308) 0.05 (0.975)
Model 4 1.855** (1.248 - 2.758) 1.293* (1.058 - 1.580) 1.123 (0.890 - 1.418) 1.147* (1.023 - 1.287) <0 (1)
Model 5 1.824** (1.288 - 2.583) 1.267* (1.041 - 1.542) 1.123 (0.854 - 1.476) 1.136 (1.014 - 1.273) <0 (1)
Model 6 -- -- 1.284* (1.047 - 1.574) 1.131 (0.860 - 1.487) -- -- --
* p < 0.025 ; ** p < 0.01
Model 1: adjusted for age, sex, and urinary creatinine concentration
Model 2: further adjusted for race/ethnicity, income, smoking, body mass index, and waist circumference
Model 3: veteran/military status, citizenship status, marital status, household size, pregnancy status, language at subject interview, health insurance coverage, and
employment status in the prior week
Model 4: consumption of bottled water in the past 24 hrs, consumption of alcohol, and annual consumption of tuna fish
Model 5: presence of emotional support in one’s life, being on a diet, using a water treatment device, access to a routine source of health care, vaccinated for Hepatitis A or
B, consumption of dietary supplements (vitamins or minerals), and inability to purchase balanced meals on a consistent basis
Model 6: concentration of (2-ethylhexyl) phthalate (MEHP), mono-isobutyl phthalate (MiBP), and mono-n-butyl phthalate (MeBP)
†. Hausman test was performed to compare the fit of each model to the prior model in the pooled data
doi: 10.1371/journal.pone.0079944.t002
Table 3. Logistic regression analysis of self-reported diabetes per standard deviation increase of Bisphenol A exposure for
NHANES 03-04 (N = 1,455), 05-06 (N = 1,498), 07-08 (N = 1,705), and a pooled sample (N = 4,658).
 NHANES 03-04 NHANES 05-06 NHANES 07-08 Pooled   
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Hausman Statistic (p) †
Model 1 1.404** (1.210 - 1.628) 0.984 (0.805 - 1.203) 0.722 (0.526 - 0.991) 1.053 (0.958 - 1.157) --
Model 2 1.400** (1.245 - 1.574) 0.975 (0.723 - 1.316) 0.710 (0.506 - 0.995) 1.074 (0.980 - 1.176) <0 (1)
Model 3 1.358** (1.237 - 1.491) 1.032 (0.847 - 1.258) 0.709 (0.496 - 1.015) 1.077 (0.986 - 1.176) <0 (1)
Model 4 1.359** (1.187 - 1.556) 1.037 (0.866 - 1.241) 0.711 (0.487 - 1.038) 1.072 (0.982 - 1.170) <0 (1)
Model 5 1.398** (1.183 - 1.653) 1.008 (0.861 - 1.181) 0.716 (0.500 - 1.025) 1.065 (0.973 - 1.166) 0.099 (0.952)
Model 6 -- -- 1.007 (0.859 - 1.182) 0.699 (0.464 - 1.052) -- -- --
* - p < 0.025 ; ** p < 0.01
Model 1: adjusted for age, sex, and urinary creatinine concentration
Model 2: further adjusted for race/ethnicity, income, smoking, body mass index, and waist circumference
Model 3: veteran/military status, citizenship status, marital status, household size, pregnancy status, language at subject interview, health insurance coverage, and
employment status in the prior week
Model 4: consumption of bottled water in the past 24 hrs, consumption of alcohol, and annual consumption of tuna fish
Model 5: presence of emotional support in one’s life, being on a diet, using a water treatment device, access to a routine source of health care, vaccinated for Hepatitis A or
B, consumption of dietary supplements (vitamins or minerals), and inability to purchase balanced meals on a consistent basis
Model 6: concentration of (2-ethylhexyl) phthalate (MEHP), mono-isobutyl phthalate (MiBP), and mono-n-butyl phthalate (MeBP)
†. Hausman test was performed to compare the fit of each model to the prior model in the pooled data
doi: 10.1371/journal.pone.0079944.t003
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LLOD and in the top percentile led to another large increase,
nearly ~20%, in the estimated ORs from the pooled data
(Tables S5 and S6). Comparable changes, often similar in
direction but smaller in magnitude, were observed in log-linear
and diabetes-related regression models with the application of
exclusion criteria. Statistical significant ORs for diabetes, by the
linear model, were only observed after exclusion of subjects
>80.1 ng/ml in the pooled sample. Better model fits, or lower
AIC and BIC, were observed after applying exclusion criteria
(Table S13 and S14).
Finally, Table 5 provides estimated ORs from the dose-
response regression analysis in the pooled sample. Although
significant ORs were not observed, an upward trend in CHD
risk was observed across BPA quartiles. Individuals in the
25-50th percentile of BPA exposure, 1.1-2.2 ng/ml, did not
appear to be at increased risk for CHD with respect to the
referent group. Unlike CHD, significance was achieved in the
Table 4. Log-linear analysis of self-reported CHD per ten-fold increase in Bisphenol A exposurefor NHANES 03-04 (N =
1,455), 05-06 (N = 1,498), 07-08 (N = 1,705), and a pooled sample (N = 4,658).
 NHANES 03-04 NHANES 05-06 NHANES 07-08 Pooled   
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Hausman Statistic (p) †
Model 1 1.527 (0.918 - 2.542) 1.126 (0.698 - 1.815) 1.416 (0.920 - 2.180) 1.320 (1.025 - 1.698) --
Model 2 1.860 (1.023 - 3.383) 1.124 (0.741 - 1.706) 1.493 (0.994 - 2.242) 1.326 (1.035 - 1.698) 0.123 (0.941)
Model 3 1.815* (1.155 - 2.852) 1.169 (0.790 - 1.730) 1.564 (1.039 - 2.356) 1.323* (1.037 - 1.688) 0.005 (0.998)
Model 4 1.661** (1.184 - 2.331) 1.233 (0.776 - 1.960) 1.616 (1.048 - 2.493) 1.302 (1.008 - 1.681) 0.271 (0.873)
Model 5 1.584 (1.066 - 2.354) 1.178 (0.765 - 1.815) 1.649 (1.025 - 2.654) 1.280 (0.993 - 1.649) 0.476 (0.788)
Model 6 -- -- 1.460 (0.893 - 2.386) 1.679 (1.007 - 2.801) -- -- --
* p < 0.025 ; ** p < 0.01
Model 1: adjusted for age, sex, and urinary creatinine concentration
Model 2: further adjusted for race/ethnicity, income, smoking, body mass index, and waist circumference
Model 3: veteran/military status, citizenship status, marital status, household size, pregnancy status, language at subject interview, health insurance coverage, and
employment status in the prior week
Model 4: consumption of bottled water in the past 24 hrs, consumption of alcohol, and annual consumption of tuna fish
Model 5: presence of emotional support in one’s life, being on a diet, using a water treatment device, access to a routine source of health care, vaccinated for Hepatitis A or
B, consumption of dietary supplements (vitamins or minerals), and inability to purchase balanced meals on a consistent basis
Model 6: concentration of (2-ethylhexyl) phthalate (MEHP), mono-isobutyl phthalate (MiBP), and mono-n-butyl phthalate (MeBP)
†. Hausman test was performed to compare the fit of each model to the prior model in the pooled data
doi: 10.1371/journal.pone.0079944.t004
Table 5. Log-linear analysis of self-reported diabetes per ten-fold increase in Bisphenol A exposure for NHANES 03-04 (N =
1,455), 05-06 (N = 1,498), 07-08 (N = 1,705), and a pooled sample (N = 4,658).
 NHANES 03-04 NHANES 05-06 NHANES 07-08 Pooled   
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Hausman Statistic (p) †
Model 1 1.562** (1.323 - 1.844) 1.203 (0.947 - 1.529) 0.961 (0.790 - 1.170) 1.209** (1.071 - 1.365) --
Model 2 1.548** (1.315 - 1.823) 1.171 (0.838 - 1.636) 0.967 (0.812 - 1.151) 1.197* (1.039 - 1.380) (0.146)
Model 3 1.524** (1.295 - 1.794) 1.223 (0.883 - 1.695) 0.959 (0.792 - 1.163) 1.205* (1.048 - 1.386) (<0)
Model 4 1.476** (1.286 - 1.694) 1.250 (0.879 - 1.777) 0.934 (0.756 - 1.153) 1.198* (1.040 - 1.380) (0.446)
Model 5 1.492** (1.267 - 1.757) 1.230 (0.894 - 1.694) 0.932 (0.759 - 1.146) 1.202** (1.049 - 1.377) (0.026)
Model 6 -- -- 1.214 (0.881 - 1.672) 0.870 (0.679 - 1.115) -- -- --
* p < 0.025 ; ** p < 0.01
Model 1: adjusted for age, sex, and urinary creatinine concentration
Model 2: further adjusted for race/ethnicity, income, smoking, body mass index, and waist circumference
Model 3: veteran/military status, citizenship status, marital status, household size, pregnancy status, language at subject interview, health insurance coverage, and
employment status in the prior week
Model 4: consumption of bottled water in the past 24 hrs, consumption of alcohol, and annual consumption of tuna fish
Model 5: presence of emotional support in one’s life, being on a diet, using a water treatment device, access to a routine source of health care, vaccinated for Hepatitis A or
B, consumption of dietary supplements (vitamins or minerals), and inability to purchase balanced meals on a consistent basis
Model 6: concentration of (2-ethylhexyl) phthalate (MEHP), mono-isobutyl phthalate (MiBP), and mono-n-butyl phthalate (MeBP)
†. Hausman test was performed to compare the fit of each model to the prior model in the pooled data
doi: 10.1371/journal.pone.0079944.t005
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majority of ORs for diabetes, but there was no dose-response
relationship, with the middle upper quartile showing reduced
risk with respect to the middle lower quartile. Expanded dose-
response analysis for each NHANES cycles are reported in
Tables S15 and S16. Significant interactions between BPA and
NHANEs cycle were observed in the linear model, but not in
the log-linear nor dose-response models (Table S22-S23).
Discussion
The potential toxicity of BPA has become a topic of much
debate among academics and policy-makers. The controversy
expanded beyond the teratogenic effects of BPA when Lang et
al reported statistically significant associations between BPA
and self-reported CHD and diabetes in the 03-04 NHANES
cycle [21]. Several subsequent studies have explored the issue
further by altering the statistical model and/or expanding the
data set to include more NHANES data [22-24,26]. Our study is
meant to replicate the work of prior studies, expand the
analysis to three NHANES cycles (03-04, 05-06, and 07-08),
and to explore the issues of potential confounding and
functional form.
Our first major finding was that the ORs were generally
robust to sources of potential confounding, either slightly
increasing or remaining stable as we added more covariates to
each model. We expanded upon previous studies to include
four categories of potential confounders: additional
demographic information, differential exposure to potential BPA
sources, likelihood to engage in healthy behaviours, and
concurrent phthalate exposure. From the pooled data from
Table 2 and Table 3, we see at most a 5% change in the
estimated ORs with each expansion of the regression model.
Further, all Hausman tests failed to achieve significance,
confirming that no one block of covariates significantly affected
the estimation of associations between BPA and CHD/diabetes
risk. Comparable results were observed across individual
NHANES cycles and log-linear regression models. The stability
across covariate models confirms that the estimated ORs were
robust. However, our study was limited to assessment of
confounders that were consistently reported in NHANES
across three survey cycles. For example, additional sources of
exposure may have also affected the health outcomes, such as
number of meals away from home [9], use of hemodialysis [37],
use of dental sealants [38], use of microwave containers [39],
and more. Moreover, CHD medications, namely diuretics, may
act to increase a subject’s BPA clearance rate, potentially
creating a spurious relationship between BPA and CHD [24].
We also examined whether consistency was achieved
across NHANES cycles and the pooled data, and found ORs to
vary considerably across cycles. Figure 1 demonstrates that
BPA exposure was highest in the 03-04 cycle, and relatively
similar from 05-06 to 07-08. Mean BPA concentration
decreased from 4.76 (SD = 6.78) to 4.16 (SD = 13.28) to 3.77
ng/ml (SD = 7.00) in 03-04, 05-06, and 07-08 respectively. It is
unlikely that decreases in BPA exposure from 03-04 to 05-06
can be attributed to increased public awareness/concern of
BPA. Major media outlets - including the New York Times,
NPR, and NBC News – did not start reporting the potential
harms of BPA until after the first half of the 05-06 NHANES
cycle [40-42]. Silver et al. have suggested that the unusually
high BPA concentrations in 03-04 may be attributed to a
sampling error [24]. The authors used this argument to explain
the unusual difference in effect estimates between the 03-04
data and other NHANES cycles (Table 3) in the assessment of
diabetes. Although this result was replicated in our study, the
pattern did not carry over to the analysis of CHD.
Further complicating the matter is lack of consistency across
linear and log-linear models in the assessment of CHD risk
(Tables 2 and 4). The log-linear model failed to achieve
significance in the pooled sample, while the linear model did
(note that 03-04 yielded significant OR estimates in both
instances, while 05-06 and 07-08 samples were generally non-
significant). A similar inconsistency was observed in the
analysis of self-reported diabetes (Tables 3 and 5), where
statistical significance was subsequently achieved in the
pooled sample after application of the log-transformation. This
result is representative of the second major finding of our
study: observed ORs, were sensitive to the functional-form of
the applied statistical model. This is disconcerting because
medical theories offer little guidance on the appropriate choice
of functional form. Several papers have advocated for
researchers to use a log-linear model as it better estimates risk
in samples with high-exposure regions [24,36]. AIC and BIC
generally indicated that the log-linear model fit the data better
(Table S13 and S14), but changes in criterion were very small
across functional-forms. We advise researchers to report
results from multiple specifications to identify any potential
discrepancies while also allowing readers to judge for
themselves. Further, researchers should be statistically
rigorous when reporting across multiple outcomes as ORs
were noted to lose significance after application of the
Bonferoni correction.
We also attempted to explore if there was a dose-response
relationship between BPA and health and explore the influence
of outliers. While we find a pattern of increasing ORs consistent
for CHD, the estimates were not statistically significant. More
dramatic results were observed for diabetic outcomes when a
dose-response model was applied (Table 6): estimates were
statistically significant, but ORs supported a highly nonlinear
relationship. Furthermore, outliers also influenced results.
Previous papers have omitted subjects with BPA greater than
>80.1 ng/ml, but this criteria is insufficient as it is arbitrarily
based off the range of values observed in the 03-04 NHANES
dataset [23]. Exclusion of subjects with a urinary BPA
concentration in excess of >80.1 ng/ml led to a ~30% and
~15% increase in the estimated CHD and diabetes ORs
respectively. Even larger increases, ~60% and
~20%respectively, were observed as subjects below the LLOD
and in the top percentile were excluded. The log-linear model
was less sensitive to the effects of inclusion/exclusion criteria
because the log-transformation tends to dampen the influence
of outliers. While the use of dummy variables can alleviate the
influence of outliers, our results for diabetes were inconsistent
with a dose-response relationship.
Unfortunately, animal studies offer little clarity in the analysis
of BPA. It has been argued that BPA may induce harmful
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biological changes as both an estrogen agonist and androgen
antagonist [43,44]. Another study directly suggested that the
estrogenic effects of BPA can induce insulin resistance in mice
[45]. However, these highly suggestive results often remain
isolated. In an extensive review, Hengstler et al. report that
animal studies generally yielded inconsistent and opposing
results, often pitting academic and industry researchers against
one another [3]. Further complicating matters, BPA metabolism
varies greatly across different species, making it difficult to
extrapolate animal models to humans [46]. Significantly more
research is required to substantiate any mechanistic
pathway(s) that explain how BPA induces adverse effects in
the human body.
Significant interactions between BPA and NHANEs cycle
were observed in the linear model, but not in the log-linear or
dose-response models. We are unfortunately unable to test the
Table 6. Dose-response regression analysis of both CHD
and diabetes in the pooled NHANES data (N = 4,658).
  CHD  Diabetes
 [BPA] (ng/ml) OR (95% CI)  OR (95% CI)
Model 1 <1.1 Ref --  Ref --
 1.2-2.2 0.663 (0.346 - 1.272) 1.682** (1.252 - 2.258)
 2.3-4.2 1.118 (0.606 - 2.066) 1.593 (1.036 - 2.451)
 >4.2 1.771 (0.875 - 3.583) 1.940** (1.332 - 2.824)
Model 2 <1.1 Ref --  Ref --
 1.2-2.2 0.617 (0.331 - 1.149) 1.614** (1.144 - 2.275)
 2.3-4.2 1.069 (0.575 - 1.987) 1.493 (0.947 - 2.355)
 >4.2 1.676 (0.861 - 3.262) 1.806** (1.170 - 2.787)
Model 3 <1.1 Ref --  Ref --
 1.2-2.2 0.618 (0.332 - 1.150) 1.632** (1.147 - 2.321)
 2.3-4.2 1.088 (0.584 - 2.025) 1.529 (0.989 - 2.363)
 >4.2 1.657 (0.865 - 3.177) 1.812** (1.170 - 2.805)
Model 4 <1.1 Ref --  Ref --
 1.2-2.2 0.563 (0.291 - 1.092) 1.610* (1.122 - 2.311)
 2.3-4.2 1.063 (0.533 - 2.116) 1.476 (0.958 - 2.276)
 >4.2 1.610 (0.810 - 3.200) 1.793* (1.147 - 2.801)
Model 5 <1.1 Ref --  Ref --
 1.2-2.2 0.520 (0.250 - 1.084) 1.443 (0.982 - 2.119)
 2.3-4.2 1.006 (0.508 - 1.994) 1.512 (0.998 - 2.289)
 >4.2 1.520 (0.774 - 2.987) 1.760* (1.137 - 2.724)
* p < 0.025 ; ** p < 0.01
Model 1: adjusted for age, sex, and urinary creatinine concentration
Model 2: further adjusted for race/ethnicity, income, smoking, body mass index,
and waist circumference
Model 3: veteran/military status, citizenship status, marital status, household size,
pregnancy status, language at subject interview, health insurance coverage, and
employment status in the prior week
Model 4: consumption of bottled water in the past 24 hrs, consumption of alcohol,
and annual consumption of tuna fish
Model 5: presence of emotional support in one’s life, being on a diet, using a water
treatment device, access to a routine source of health care, vaccinated for
Hepatitis A or B, consumption of dietary supplements (vitamins or minerals), and
inability to purchase balanced meals on a consistent basis
doi: 10.1371/journal.pone.0079944.t006
reason behind these inconsistencies across years and models
without additional information, but we suspect issues with the
quality of BPA measurement is one important factor. Urinary
output, and its chemical content, varies greatly over a 24hr
period. Studies have suggested that single spot urinary
samples are reasonable estimates for determining average
population exposure to BPA, but only moderately sensitive in
estimating an individual’s daily BPA intake [47,48]. Our
analysis could better account for temporal variability in BPA
concentration by adjusting for total 24hr urinary output [6,9], but
this variable was not available in any NHANES cycle. Further,
roughly 8% of the pooled sample (~366 subjects) was below
the LLOD. This creates an unfortunate situation in which values
below the LLOD are considered differently than values above
the LLOD (where the former were uniformly assigned a value
of LLOD/√2 and the latter measured on continuous spectrum).
Without further information on the nature of error below the
LLOD, we cannot rule out bias due to mismanagement of non-
detects in our statistical models [49]. Finally, and potentially
most importantly, single-spot urine assessment is a poor
substitute for chronic exposure to BPA. In this regard, it is
difficult to bridge the gap from cross-sectional studies to causal
theories that link sustained insult, via BPA’s endocrine
disruption, to the underlining pathologies of lifestyle diseases,
such as CHD and diabetes.
Conclusions
The National Institute of Environmental Health Sciences
recently allocated 30 million dollars to fund BPA research [50].
We hope that this study can inform researchers in their
statistical modelling. While the results were generally robust to
the sequential addition of more covariates, the ORs changed
dramatically, sometimes even flipping signs, across statistical
models. Unfortunately we could not pin down the reason for
these changes. Therefore, our recommendation is that it is
essential to report results from multiple specifications with
different assumptions about BPA measurement and its
potential health effects in order for these observational
analyses to be informative on the health effects of BPA.
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